Abstract
A novel structure-based approach for site of metabolism prediction has been developed. This knowledge-based method consists of three steps: (1) generation of possible metabolites, (2) docking the predicted metabolites to the CYP binding site and (3) selection of the most probable metabolites based on their complementarity to the binding site. As a proof of concept we evaluated our method by using MetabolExpert for metabolite generation and Glide for docking into the binding site of the CYP2C9 crystal structure. Our method could identify the correct metabolite among the three best-ranked compounds in 69% of the cases. The predictive power of our knowledge-based method was compared to that achieved by substrate docking and two alternative literature approaches.







Similar content being viewed by others
References
van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192–204
Ahlström MM, Ridderström M, Zamora I (2007) CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. J Med Chem 50:5382–5391
Trunzer M, Faller B, Zimmerlin A (2009) Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J Med Chem 52:329–335
Vasanthanathan P, Hritz J, Taboureau O, Olsen L, Jørgensen FS, Vermeulen NP, Oostenbrink C Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands. J Chem Inf Model 49:43–52
Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, Benson DE, Sweet RM, Ringe D, Petsko GA, Sligar SG (2000) The catalytic pathway of cytochrome p450cam at atomic resolution. Science 287:1615–1622
Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464–468
Pang KS (2009) Safety testing of metabolites: expectations and outcomes. Chem Biol Interact 179:45–59
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208
Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538
Sykes MJ, McKinnon RA, Miners JO (2008) Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. J Med Chem 51:780–791
Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630–35637
Polgár T, Menyhárd DK, Keseru GM (2007) Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. J Comput Aided Mol Des 9:539–548
Otyepka M, Skopalík J, Anzenbacherová E, Anzenbacher P (2007) What common structural features and variations of mammalian P450 s are known to date? Biochim Biophys Acta 1770:376–389
Bikádi Z, Hazai E (2008) In silico description of differential enantioselectivity in methoxychlor O-demethylation by CYP2C enzymes. Biochim Biophys Acta 1780:1070–1079
Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP (2000) A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem 43:2789–2796
Afzelius L, Zamora I, Ridderström M, Andersson TB, Karlén A, Masimirembwa CM (2001) Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 59:909–919
de Groot MJ, Alex AA, Jones BC (2002) Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem 45:1983–1993
Zamora I, Afzelius L, Cruciani G (2003) Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J Med Chem 46:2313–2324
Boyer S, Zamora I (2002) New methods in predictive metabolism. J Comput Aided Mol Des 5–6:403–413
Sheridan RP, Korzekwa KR, Torres RA, Walker MJ (2007) Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. J Med Chem 50:3173–3184
Peng CC, Cape JL, Rushmore T, Crouch GJ, Jones JP (2008) Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues. J Med Chem 51:8000–8011
Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, Vianello R (2005) MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970–6979
ROCS Openeye Scientific Software: Sante Fe, NM, 2006
FRED Openeye Scientific Software: Sante Fe, NM, 2005
Verkivker GM, Bouzida D, Gehlaar DK, Rejto PA, Arthurs S, Colson AB, Freer ST, Larson V, Luty BA, Marrone T, Rose PW (2000) Deciphering common failures in molecular docking of ligand-protein complexes. J Comp-Aided Mol Des 14:731–751
Ortiz de Montellano PR (2005) Cytochrome P450 structure, mechanism, and biochemistry. Kluwer Academic/Plenum Publishers, New York
Peterson JA, Graham SE (1998) A close family resemblance: the importance of structure in understanding cytochromes P450. Structure 6:1079–1085
Poulos TL, Finzel BC, Howard AJ (1986) Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. Biochemistry 25:5314–5322
Poulos TL, Finzel BC, Gunsalus IC, Wagner GC, Kraut J (1985) The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. J Biol Chem 260:16122–16130
Li H, Narasimhulu S, Havran LM, Winkler JD, Poulos TL (1995) Crystal structure of cytochrome P-450 complexe with its catalytic product, 5-Exo-Hydroxycamphor. J Am Chem Soc 117:6297–6299
Raag R, Poulos TL (1989) Crystal structure of the carbon monoxide-substrate-cytochrome P-450CAM ternary complex. Biochemistry 28:7586–7592
CompuDrug International, Inc (2003) 115 Morgan Drive, Sedona, AZ 86351, USA
Glide, version 5.0 (2008) Schrödinger, LLC, New York
National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/sites/entrez Accessed 2009 February
ChemAxon http://www.chemaxon.com Accessed 2009 February
CompuDrug http://www.compudrug.com Accessed 2009 February
He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372:16–28
LigPrep, version 2.3 (2009) Schrödinger, LLC, New York
McGaughey GB, Sheridan RP, Bayly CI, Culberson JC, Kreatsoulas C, Lindsley S, Maiorov V, Truchon JF, Cornell WD (2007) Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model 47:1504–1519
Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, Lee RE (2009) Validation of molecular docking programs for virtual screening against Dihydropteroate synthase. J Chem Inf Model 49:444–460
Kontoyianni M, McClellan LM, Sokol GS (2004) Evaluation of docking performance: comparative data on docking algorithms. J Med Chem 47:558–565
Lee H, Ortiz de Montellano PR, McDermott AE (1999) Deuterium magic angle spinning studies of substrates bound to cytochrome P450. Biochemistry 38:10808–10813
UNITY, Tripos Inc. 1699 South Hanley Road St. Louis, MO 63144-2319 USA
Zhou D, Afzelius L, Grimm SW, Andersson TB, Zauhar RJ, Zamora I (2006) Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab Dispos 6:976–983
Acknowledgments
The authors would like to thank Márk Sándor for his useful comments.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tarcsay, Á., Kiss, R. & Keserű, G.M. Site of metabolism prediction on cytochrome P450 2C9: a knowledge-based docking approach. J Comput Aided Mol Des 24, 399–408 (2010). https://doi.org/10.1007/s10822-010-9347-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-010-9347-3